CRISPR/Cas and Gene Editing for HIV - Paula Cannon

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Dual Maintenance for HIV: Why Fix it if it's not Broken? (Debate: Discussion)

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Dual Maintenance for HIV: Why Fix it if it's not Broken? (Debate: Pro) - Jose Arribas

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Dual Maintenance for HIV: Why Fix it if it's not Broken? (Debate: Con) - Andrew Hill

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Clinical Case Presentation - Catia Marzolini

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Long-Acting HIV Drugs for Treatment: Data and Potential Implementation - Laura Waters

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Long-Acting HIV Drugs for Treatment: Data and Potential Implementation - Charles Flexner

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Improved Long-Acting Drug Delivery: What are the Technologies? - Andrew Owen

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Pharmacological Treatment of NASH - Sven Francque

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Novel Antiviral and Immune Targets to Cure HBV - Fabien Zoulim

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

The "Third Wave" of TB Drug Development: What's on the Horizon - Kelly Dooley

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

50% Adherence is Enough with Modern ARVs, Right? - Terrence Blaschke

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019